Retatrutide vs Thymulin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Thymulin
Thymulin (Facteur Thymique Sérique) is a zinc-dependent nonapeptide hormone produced by thymic epithelial cells. It plays important roles in T-cell differentiation and immune system maturation.
Full details →Side-by-Side Comparison
| Aspect | Retatrutide | Thymulin |
|---|---|---|
| Mechanism | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. | Requires zinc for biological activity. Promotes T-cell differentiation, modulates cytokine production, and influences neuroendocrine function. Levels decline significantly with age. |
| Typical Dosage | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. | Research protocols vary. Often studied alongside zinc supplementation. Typical research doses in the microgram range. |
| Administration | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. | Subcutaneous or intramuscular injection in research settings. Requires adequate zinc status for activity. |
| Side Effects | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. | Limited data on exogenous administration. Theoretical effects on immune function require monitoring. |
| Best For |